Berlin-based biotech startup MyoPax has secured an undisclosed pre-seed investment from IBB Ventures through its B# Plus financing initiative. The company is the first startup to receive funding through B# Plus, which supports early-stage deeptech companies with at least one female founder. The investment was announced on October 13, 2026.
The funding will support MyoPax in developing its pharmaceutical manufacturing processes, preparing its first therapeutic candidate for clinical development and expanding its cell and gene therapy platform. The investment complements funding awarded through the European Union’s European Innovation Council (EIC) Accelerator programme.
Launched in 2022, MyoPax is a spin-off from Charité Universitätsmedizin Berlin and the Max Delbrück Center. Its founding team comprises Prof. Dr. Simone Spuler, Dr. Verena Schöwel-Wolf and Dr. Diane Seimetz, who joined as a co-founder in 2023. Schöwel-Wolf serves as the company’s CEO.
MyoPax develops regenerative therapies for muscle diseases, including genetic muscular dystrophies and conditions involving muscle tissue damage. Its technology combines muscle stem cell therapies with CRISPR/Cas gene editing to develop treatments that aim to repair disease-causing genetic mutations and restore muscle function.
The company’s platform includes technologies for isolating and cultivating regenerative human muscle stem cells, engineering stem cells and performing targeted gene correction. These approaches are being developed for muscle disorders with limited treatment options.
MyoPax previously received a €1.3 million loan through the BioInnovation Institute’s Venture House programme in 2022 to support its early business development. The company subsequently secured EIC Accelerator support for its regenerative gene-repair therapy development programme.
The B# Plus investment will support the next stage of manufacturing development and preparations for clinical evaluation. The initiative is an extension of Berlin’s B# pre-seed fund, managed by IBB Ventures, and focuses on deeptech startups with female founders.

